Orthocell (ASX:OCC) - Chief Scientific Officer, Minghao Zheng - The Market Herald
Chief Scientific Officer, Minghao Zheng
Source: Orthocell
Market Herald logo


Be the first with the news that moves the market
  • Regenerative medicine company Orthocell (OCC) sees its breakthrough tissue engineering study published in a US peer reviewed journal
  • The study looked at combining OCC’s CelGro with lymphatic and blood vessel cells to create tissue which can treat lymphedema in breast cancer patients
  • The regenerative medicine company says it will further explore CelGro’s development options alongside its nerve repair applications
  • Orthocell is up 2.80 per cent, trading at 55 cents at 2:20 pm AEST

Regenerative medicine company Orthocell (OCC) has seen its breakthrough tissue engineering study published in a highly regarded journal.

The study looked at combining Orthocell’s CelGro, a collagen membrane for regeneration procedures, with lymphatic and blood vessel cells to create functional lymphatic tissue. It was published in the peer-reviewed journal “Proceedings of the National Academy of Sciences of the United States of America”.

CelGro can act as a cell scaffold when implanted at the site of tissue injury, encouraging new cell growth. Cells from the regenerating tissue integrate with the collagen fibres to guide tissue regeneration.

To create the tissue for the study, researchers used cultured lymphatic and blood vessel cells on CelGro scaffolds and stretched them to simulate real life movement situations. The graft was then surgically implanted in a mouse and assessed after seven days, returning positive results.

Orthocell says its findings represent the potential to use its treatment in novel surgical treatments for patients suffering from lymphedema, a complication following breast cancer treatments that affects one in every five patients. The build-up of fluid in soft body tissues can lead to significant disfiguration, pain and discomfort, as well as a decreased range of motion. Patients can also be at risk of developing potentially life-threatening deep skin infections.   

“This study provides a new understanding of the role of CelGro in fabrication of tissue grafts for lymphatic vessel regeneration, which could have significant implications for a novel and effective surgical treatment of lymphedema,” Orthocell Chief Scientific Officer, Professor Minghao Zheng said.

There are no current curative treatment options for lymphedema and the company says non-surgical interventions do not provide ideal outcomes, making this new research imperative.

“This is exciting research that opens up potential for novel treatments addressing significant unmet medical needs in women’s health and we will explore these development options alongside our nerve repair applications,” Orthocell Managing Director Paul Anderson said.

Orthocell is up 2.80 per cent, trading at 55 cents at 2:20 pm AEST.

OCC by the numbers
More From The Market Herald
ImpediMed (ASX:IPD) - MD and CEO, Richard Carreon - The Market Herald

" ImpediMed (ASX:IPD) initiates SOZO heart failure program

ImpediMed (IPD) has initiated its SOZO heart failure program at Advocate Health Care’s Heart Institute in Chicago.    
Invex Therapeutics (ASX:IXC) - Chairman, Jason Loveridge - The Market Herald

" Invex Therapeutics (ASX:IXC) pens agreement for commercialisation of Presedin

Invex Therapeutics (IXC) has signed an agreement for the commercialisation of its treatment for neurological conditions caused by intracranial pressure.
LBT Innovations (ASX:LBT) - CEO and MD, Brent Barnes - The Market Herald

" LBT Innovations (ASX:LBT) subsidiary appoints US distributor

LBT Innovations (LBT) 50 per cent owned joint venture company, Clever Culture System (CCS), has appointed Thermo Fisher Scientific as its US distributor.
Paradigm Biopharmaceuticals (ASX:PAR) - Chief Medical Officer and Executive Director, Dr Donna Skerrett - The Market Herald

" Paradigm Biopharma (ASX:PAR) receives FDA feedback for knee osteoarthritis drug

Paradigm Biopharmaceuticals (PAR) has received feedback from US Food and Drug Administration (FDA) for its knee osteoarthritis drug.